Analytical Data
-
Gene name
MED8
- Application
-
Alternative Names
ARC32; Mediator Of RNA Polymerase II Transcription Subunit 8; Activator-recruited cofactor 32 kDa component
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96G25
-
Expression Region
Ser25~Arg268
-
Molecular Weight
30.1kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MED8, a subunit of the Mediator complex, plays a crucial role in gene transcription regulation by facilitating the communication between gene-specific regulatory proteins and the general transcription machinery. Research into MED8 has gained significant attention due to its involvement in essential cellular processes, including cell differentiation, proliferation, and response to external stimuli. It is known that the Mediator complex, comprising multiple subunits, acts as a bridge allowing transcription factors to interact with RNA polymerase II and other components of the transcriptional machinery. Abnormalities in MED8 and the Mediator complex have been linked to various diseases, including cancer, making it a potential target for therapeutic interventions. Furthermore, studies have indicated that MED8 may play a role in regulating alternative splicing and chromatin remodeling, underscoring its importance in the post-transcriptional regulation of gene expression. As a result, understanding the structural and functional properties of MED8, as well as its interactions within the Mediator complex, is essential for elucidating its role in normal physiology and disease pathology. Research efforts are focused on characterizing MED8 through techniques such as X-ray crystallography and cryo-electron microscopy, which aim to reveal its detailed structure and interactions with other proteins. This knowledge could pave the way for novel strategies in drug design and the development of targeted cancer therapies, highlighting the significance of MED8 in both basic and applied biomedical research.
